Urothelial Cancers

• ESMO Preceptorship on Metastatic Bladder and Kidney Cancer Zurich November 2018
• Participants Clinical Case Discussion: A Case of Toxicity in Bladder Cancer Treated with Immuno-therapy
• Debate: No, Systemic Chemotherapy is Not the Standard for Metastatic Urothelial Cancer
• Debate: Yes, Systemic Chemotherapy is the Standard for Metastatic Urothelial Cancer
• Metastatic Bladder Cancer: Immunotherapy
• Metastatic Bladder Cancer: Chemotherapy
• Radiotherapy in Metastatic Urothelial Cancer and RCC
• RCC: Surgery in Metastatic Disease
• The Role of Surgery in Metastatic Bladder Cancer
• The Search for Biomarkers in Bladder Cancer
• 10th European Multidisciplinary congress on Urological Cancers
• ESMO Preceptorship on Metastatic Bladder and Kidney Cancer Singapore September 2018
• Bladder and Renal Cell Cancer
• Congress Highlights 1 - Genitourinary tumours, non-prostate
• Neo-adjuvant ipilimumab and nivolumab in high risk resectable bladder urothelial cancer (NABUCCO)
• ATLAS: a phase 2, open-label study of rucaparib in patients (pts) with locally advanced (unresectable) or metastatic urothelial carcinoma
• BAYOU: Phase 2 Study of Efficacy and Safety of Durvalumab plus Olaparib as First-line Therapy in Platinum-ineligible Patients (pts) with Stage IV U...
• Phase 2/3 study of rogaratinib versus chemotherapy in patients with locally advanced or metastatic urothelial carcinoma selected based on FGFR1/3 m...
• A phase II study investigating the safety and efficacy of neoadjuvent atezolizumab in muscle invasive bladder cancer (ABACUS)
• Interim results of fight-201, a phase 2, open-label, multicenter study of INCB054828 in patients (pts) with metastatic or surgically unresectable u...
• Impact of Prognostic Factors and Risk Groups on Overall Survival (OS) in Patients Treated With Pembrolizumab vs Investigator’s Choice Chemotherapy...
• Biological features and clinical outcomes in atezolizumab (atezo)-treated patients (pts) with metastatic urothelial cancer (mUC) of the upper vs lo...
• Impact of different programmed cell death ligand-1 (PD-L1) expression algorithms on patient selection and durvalumab efficacy in urothelial carcino...
• CD103+ Tissue-resident CD8+ T Cells Correlate with Protective Anti-tumoral Immune Responses in Muscle-invasive Bladder Cancer Patients
• Immune-checkpoint inhibitors in previously treated patients with urothelial carcinoma: a systematic review and meta-analysis.

• « Previous
• 1
• 2
• ...
• 13
• Next »